Some researchers have explored doses at the initial titration level (for example, 0.25 mg weekly of semaglutide, which is the standard starting dose for Ozempic but subtherapeutic for glycemic control), hypothesizing that anti-inflammatory benefits might be achieved with reduced gastrointestinal side effects
Although this study has mined risk signals, because the currently available evidence is limited, we are unable to explain the different research results of inconsistencies
As we approach the end of the year, it is important that athletes and athlete support personnel understand what is new on the Prohibited List for 2024
No known contraindication, and Mayo Clinic ENDO 2025 (120 postmenopausal women) showed tirzepatide plus HRT produced 17% weight loss vs 14% for tirzepatide alone
Gallbladder disease: Rapid weight loss increases cholelithiasis risk
In follow-up studies, they said they hope to dive into their effects on substance use disorder specifically